106 related articles for article (PubMed ID: 9350184)
1. Treatment of follicular follicle centre lymphomas: current status and future perspectives.
Hiddemann W; Unterhalt M; Buske C; Sack H
J Intern Med Suppl; 1997; 740():55-62. PubMed ID: 9350184
[TBL] [Abstract][Full Text] [Related]
2. [Low-grade malignant non-Hodgkin lymphomas--current status and trends in therapy].
Hiddemann W
Ther Umsch; 1996 Feb; 53(2):123-32. PubMed ID: 8629262
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies in follicular lymphomas: current status and future perspectives.
Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Forstpointner R; Nickenig C; Unterhalt M
J Clin Oncol; 2005 Sep; 23(26):6394-9. PubMed ID: 16155025
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa for the treatment of follicular lymphomas.
Hiddemann W; Griesinger F; Unterhalt M
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S13-8. PubMed ID: 9672770
[TBL] [Abstract][Full Text] [Related]
8. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
11. [Follicle centre lymphoma: treatment results for stage I and II].
Neumann H; Blanck H; Koch R; Fiedler S; Lesche A; Herrmann T
Strahlenther Onkol; 2003 Dec; 179(12):840-6. PubMed ID: 14652673
[TBL] [Abstract][Full Text] [Related]
12. Can we cure indolent lymphomas?
Cabanillas F
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2655-9. PubMed ID: 10068269
[TBL] [Abstract][Full Text] [Related]
13. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
14. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Velasquez WS; Lew D; Grogan TM; Spiridonidis CH; Balcerzak SP; Dakhil SR; Miller TP; Lanier KS; Chapman RA; Fisher RI;
J Clin Oncol; 2003 May; 21(10):1996-2003. PubMed ID: 12743154
[TBL] [Abstract][Full Text] [Related]
15. [Follicular lymphoma].
Illés A; Krenács L; Borbényi Z
Orv Hetil; 2003 Nov; 144(46):2253-61. PubMed ID: 14702920
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of low-grade non-Hodgkin lymphomas].
Hiddemann W; Unterhalt M; Wörmann B
Praxis (Bern 1994); 1996 Mar; 85(12):357-63. PubMed ID: 8643898
[TBL] [Abstract][Full Text] [Related]
17. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
18. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
19. [Medicinal therapy of malignant lymphomas].
Aul C; Schroeder M; Giagounidis A
Radiologe; 2002 Dec; 42(12):943-53. PubMed ID: 12486548
[TBL] [Abstract][Full Text] [Related]
20. A single unit lymphoma experience: outcome in a Cape Town academic centre.
Wood L; Robinson R; Gavine L; Juritz J; Jacobs P
Transfus Apher Sci; 2007 Aug; 37(1):93-102. PubMed ID: 17931976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
